Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Hansoh Pharmaceutical Group Company Limited
  6. Summary
    3692   KYG549581067

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

(3692)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
24.95 26.9 28.4 27.85 27.6 Last
6720407 6921294 7097000 2994235 2556447 Volume
-9.76% +7.82% +5.58% -1.94% -0.90% Change
Estimated financial data (e)
Sales 2021 10 764 M 1 665 M 1 665 M
Net income 2021 3 130 M 484 M 484 M
Net cash position 2021 5 220 M 807 M 807 M
P/E ratio 2021 43,4x
Yield 2021 0,59%
Sales 2022 13 527 M 2 093 M 2 093 M
Net income 2022 3 938 M 609 M 609 M
Net cash position 2022 7 256 M 1 123 M 1 123 M
P/E ratio 2022 34,7x
Yield 2022 0,74%
Capitalization 136 B 21 030 M 21 020 M
EV / Sales 2021 12,1x
EV / Sales 2022 9,51x
Nbr of Employees 11 645
Free-Float 18,1%
More Financials
Company
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED is a China-based investment holding company principally involved in the the research and development, production and sale of pharmaceutical products. The CompanyÔÇÖs main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The CompanyÔÇÖs products are mainly used for central nervous... 
Sector
Pharmaceuticals
Calendar
09/02Earnings Release
More about the company
Ratings of Hansoh Pharmaceutical Group Company Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
07/06HANSOH PHARMACEUTICAL : Accelerate Benefits for Hepatitis B Patients! Hansoh Pha..
AQ
06/23HANSOH PHARMACEUTICAL : Pharma's Hepatitis B Drug Wins Registration Approval in ..
MT
06/23Hansoh Pharmaceutical Group Company Limited Receives Approval by the National..
CI
06/17Bosheng Pharmaceutical announced that it has received $72 million in funding ..
CI
06/16Blossom Bioscience, Ltd. announced that it has received $72 million in fundin..
CI
06/13HANSOH PHARMACEUTICAL : Pharma's Schizophrenia Drug Wins Registration Approval i..
MT
06/07HANSOH PHARMACEUTICAL : Pharma Wins Regulatory Nod to Start Clinical Trial of So..
MT
06/04Hong Kong stocks slip to end week lower
RE
05/20HANSOH PHARMACEUTICAL : Pharma to Publish Phase Three Study Results for Cancer D..
MT
05/13HANSOH PHARMACEUTICAL : Pharma's Application for New Use of Cancer Drug Accepted..
MT
05/13HANSOH PHARMACEUTICAL : Voluntary announcement - new drug application of ameile ..
PU
05/13Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of..
CI
05/10HANSOH PHARMACEUTICAL : Voluntary announcement - fda tentative approval of "bort..
PU
05/10HANSOH PHARMACEUTICAL : Pharma's Cancer Drug Wins US FDA's Tentative Nod
MT
05/10Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval ..
CI
More news
News in other languages on HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
2020HANSOH PHARMACEUTICAL : Studie - Vermögen der Milliardäre erreichen Rekord trotz..
More news
Chart HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Duration : Period :
Hansoh Pharmaceutical Group Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 22,94 CNY
Average target price 37,09 CNY
Spread / Average Target 61,7%
EPS Revisions
Managers and Directors
Hui Juan Zhong Chairman & Chief Executive Officer
Guo Qiang Lin Independent Non-Executive Director
Sheung Wai Chan Independent Non-Executive Director
Dong Tao Yang Independent Non-Executive Director
Ai Feng Lyu Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED-26.60%21 030
JOHNSON & JOHNSON9.46%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.19.42%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY46.06%221 348